Denali Appoints Carole Ho as Chief Medical Officer

South San Francisco-based Denali Therapeutics has appointed physician-scientist and industry leader Carole Ho as Chief Medical Offer and Head of Development. The company was launched earlier this year with $217M in venture capital funding and a leadership team of top researchers at Genentech with the aim to develop breakthrough therapies for neurodegenerative diseases, including ALS, Parkinson’s and Alzheimer’s disease (see May 2015 news). Dr. Ho, a neurologist who has served in leadership positions in Genentech and Johnson and Johnson, will lead translational and clinical development programs at the company.

Click here to read more.

Denali disease-ad disease-als topic-clinical topic-randd
Share this: